High-risk endometrial cancer subgroups: candidates for target-based adjuvant therapy

Gynecologic Oncology
Andrea MarianiKarl C Podratz

Abstract

To identify patients with endometrial cancer at risk for hematogenous, lymphatic, or peritoneal recurrence (or combinations of them) who might potentially benefit from target-based therapies. During a 13-year period, 915 patients had endometrial cancer managed with hysterectomy and standard adjuvant therapy. On the basis of our previous regression analyses, depth of myometrial invasion predicted the risk for hematogenous recurrence; positive lymph nodes and cervical stromal invasion predicted lymphatic recurrence; stage IV disease or combination of nonendometrioid histology, cervical stromal invasion, positive lymph nodes, and positive peritoneal cytology was predictive of peritoneal recurrence. Median follow-up was 66 months. Applying the above criteria to the population of 915 patients, 24% were considered at risk for hematogenous recurrence, 18% for lymphatic recurrence, and 16% for peritoneal recurrence. The respective relapse rates at 5 years were 28% for patients who were at risk for hematogenous recurrence, 31% for lymphatic recurrence, and 42% for peritoneal recurrence. This contrasted with less than a 5% recurrence rate in the corresponding subgroups not at risk for relapse (P < 0.001). Collectively, of the 915 patient...Continue Reading

References

Apr 15, 1985·American Journal of Obstetrics and Gynecology·P J DiSaiaJ A Blessing
Sep 15, 1985·American Journal of Obstetrics and Gynecology·J T SoperW W Johnston
Apr 1, 1997·American Journal of Obstetrics and Gynecology·J W OrrP F Orr
Sep 10, 1999·Gynecologic Oncology·K TewariM F Kohler
Feb 13, 2001·Gynecologic Oncology·A MarianiK C Podratz
Mar 1, 1994·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·P. ElliottM. Tattersall
Jan 22, 2002·Current Opinion in Obstetrics & Gynecology·Laurie Elit, Hal Hirte
Jan 30, 2002·Obstetrics and Gynecology·Neil S HorowitzTimothy P Mate
Feb 22, 2002·Gynecologic Oncology·Andrea MarianiKarl C Podratz
Apr 26, 2003·Gynecologic Oncology·Carien L CreutzbergUNKNOWN PORTEC Study Group
Apr 26, 2003·Gynecologic Oncology·Andrea MarianiKarl C Podratz

❮ Previous
Next ❯

Citations

May 17, 2005·Gynecologic Oncology·Andrea MarianiKarl C Podratz
Oct 3, 2006·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·I KalogiannidisI Vergote
Oct 20, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·R BerrettaG B Nardelli
Feb 16, 2013·International Journal of Clinical Oncology·Mariam M AlHilli, Andrea Mariani
May 1, 2012·International Journal of Radiation Oncology, Biology, Physics·Brandon M BarneyMichael G Haddock
Jul 12, 2011·Gynecologic Oncology·Jamie N Bakkum-GamezKarl C Podratz
Jan 5, 2008·Mayo Clinic Proceedings·Jamie N Bakkum-GamezSean C Dowdy
Jul 17, 2007·Annals of Diagnostic Pathology·Nadia IsmiilMahmoud A Khalifa
Jan 17, 2014·The Journal of Obstetrics and Gynaecology Research·Sokbom KangHidemichi Watari
Oct 6, 2009·American Journal of Obstetrics and Gynecology·Shulan MaSun-Wei Guo
Jan 21, 2011·American Journal of Obstetrics and Gynecology·Nicanor I Barrena MedelJason D Wright
Aug 13, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Jone TrovikHelga B Salvesen
May 21, 2013·Gynecologic Oncology·Stefano UccellaAndrea Mariani
Jun 9, 2016·Expert Review of Anticancer Therapy·Valentina ZanfagninAndrea Mariani
May 16, 2009·International Journal of Surgical Pathology·Maria Luisa CarcangiuPaolo Sala
Jun 13, 2017·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Murat OzTayfun Gungor
Mar 9, 2012·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Ha-Jeong KimByoung-Gie Kim
Apr 7, 2007·International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists·Hermann Brustmann
Sep 1, 2007·Current Opinion in Oncology·Frederic AmantIgnace Vergote
Dec 25, 2009·Menopause : the Journal of the North American Menopause Society·Gabriele SiestoPierfrancesco Bolis
Nov 5, 2010·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Andrea MarianiSean C Dowdy
Nov 5, 2010·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Thomas Hogberg
Mar 5, 2009·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Henry C KitchenerUNKNOWN Endometrial Cancer Working Group of the Gynecologic Cancer Intergroup
Aug 12, 2005·Current Opinion in Oncology·Katharina Kieser, Amit M Oza
Jul 10, 2009·Expert Opinion on Pharmacotherapy·Nicanor I Barrena MedelThomas J Herzog
Sep 18, 2014·The American Journal of Surgical Pathology·Niamh ConlonRobert A Soslow
Aug 12, 2017·Cancer Biomarkers : Section a of Disease Markers·Mitra Modarres-GilaniRoghaiyeh Nourizadeh
Jun 22, 2007·International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists·Nadia D IsmiilMahmoud A Khalifa
Jun 27, 2021·Revista Española De Medicina Nuclear E Imagen Molecular·Edel Noriega-ÁlvarezÁngel M Soriano Castrejón

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.